First Al-Noor Modaraba (PSX:FANM)

Intercept Pharmaceuticals Cash Flow Statement

Financials in millions PKR. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Net Income	-8.14	0.39	0.53	2.31	0.65	-0.2
Depreciation & Amortization	2.77	0.77	0.78	1.19	1.18	1.55
Other Amortization	-	-	-	0.52	1.96	21.11
Loss (Gain) From Sale of Assets	-	-	-	-0.01	-0.81	-3.06
Loss (Gain) From Sale of Investments	-8.01	0.55	5.42	9.15	2.74	4.06
Loss (Gain) on Equity Investments	0.67	-1.41	0.15	-0.85	-2.49	-1.06
Other Operating Activities	20.96	2.84	-3.31	-0.48	-0.93	-5.17
Change in Accounts Receivable	-1.62	-1.04	-0.39	-0.06	0.08	4.54
Change in Inventory	-67.96	32.72	-111.38	-	-	53.98
Change in Accounts Payable	3.59	0.04	-1.83	-2.57	0.5	-3.7
Change in Other Net Operating Assets	22.38	33.4	36.94	26.91	43.27	-102.06
Operating Cash Flow	-26.91	68.26	-73.08	36.11	46.17	-30
Operating Cash Flow Growth	-	-	-	-21.78%	-	-
Capital Expenditures	-0.1	-0.1	-0.34	-0.72	-0.23	-2.16
Sale of Property, Plant & Equipment	-0.45	-	-	0.03	0.81	4.61
Investment in Securities	-8.42	-	-	-	-	-
Other Investing Activities	-29.31	1.41	1.53	0.62	3.08	2.88
Investing Cash Flow	-38.28	1.31	1.2	-0.08	3.66	5.33
Net Cash Flow	-65.19	69.56	-71.89	36.04	49.83	-24.67
Free Cash Flow	-27.01	68.15	-73.42	35.39	45.94	-32.16
Free Cash Flow Growth	-	-	-	-22.97%	-	-
Free Cash Flow Margin	-80.75%	195.51%	-207.89%	93.99%	171.48%	-105.69%
Free Cash Flow Per Share	-1.21	2.95	-3.18	1.53	1.99	-1.39
Cash Interest Paid	0	-	-	-	-	-
Cash Income Tax Paid	4.22	4.76	2.46	1.29	0.79	1.06
Levered Free Cash Flow	-76.06	34.07	-108.59	28.74	-16.16	65.6
Unlevered Free Cash Flow	-76.06	34.07	-108.59	28.74	-16.16	65.6
Change in Net Working Capital	77.37	-32.28	113.83	-21.07	17.82	-47.13

Source: S&P Global Market Intelligence. Standard template. Financial Sources.